DS
REGENXBIO Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RGX-314 | Wet Age-related Macular Degeneration (wAMD) | Phase 2 |
| RGX-202 | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 |
| RGX-121 | Mucopolysaccharidosis Type II (MPS II, Hunter syndrome) | Phase 1/2 |
| RGX-181 | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) | Preclinical |
| RGX-381 | Ocular manifestations of FA Deficiency (FAD) | Phase 1/2 |
| ABBV-RGX-314 | Wet AMD & Diabetic Retinopathy | Phase 3 |
Leadership Team at REGENXBIO
KT
Kenneth T. Mills
President & Chief Executive Officer, Director
PJ
Patrick J. Christmas II, J.D.
Chief Legal Officer & Corporate Secretary
CM
Curran M. Simpson
Chief Operating Officer & Chief Technology Officer
DO
Dr. Olivier Danos
Chief Scientific Officer (Senior Vice President)
VV
Vittal Vasista, CFA
Chief Financial Officer
DT
Dr. Timothy R. Miller
Co-Founder, Former President & CEO, Director
DJ
Dr. James M. Wilson
Co-Founder, Director, Head of Scientific Advisory Board
DK
Dr. Katherine A. High
Co-Founder, Director
DJ
Dr. Jeffrey S. Bartlett
Senior Vice President, Head of Technical Operations
DA
Dr. Alexei A. Lukashev
Vice President, Intellectual Property